• OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors


    Read more
  • Translational Accelerator


  • Dosing of First Patient with investigational agent OMO-1


    Read more
  • OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

  • OCTIMET Oncology NV awarded €1.077 million R&D grant from VLAIO

  • FDA Approves OCTIMET’s Investigational New Drug Application to evaluate OMO-1 in patients

  • OCTIMET Oncology announces the appointment of Shelley Margetson as CEO

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

Portfolio

  • MET protein (green) in untreated H1993 lung cancer cells. Counterstained for DNA (blue).
  • Phospho MET protein (red) in untreated H1993 lung cancer cells. Counterstained for DNA (blue).
  • MET protein (green) in OMO treated H1993 lung cancer cells. Counterstained for DNA (blue).
  • Phospho MET protein (red) in OMO treated H1993 lung cancer cells. Counterstained for DNA (blue).

Images courtesy of Letizia Lanzetti - Membrane Trafficking Laboratory - Candiolo Cancer Institute- FPO, IRCCS - Torino (Italy)

News

Our team

  • Shelley Margetson, CEO

    Shelley Margetson has worked in various European biotech companies for close to 20 years. Prior to joining OCTIMET, she was the CEO of Gadeta, and previously CFO at Merus (NASDAQ: MRUS) where she played a pivotal role in their initial public listing on the Nasdaq in May 2016.
  • Tim Perera, PhD, CSO, Founder

    Tim has more than 25 years global pharma experience in drug development. Before setting up Octimet he was Global Discovery Leader Lung Disease Area at J&J. He has led 4 discovery projects that reached clinical stage.
  • Ann Meulemans, PhD, CDO

    Ann has more than 25 years experience in product development and strategy. She brought more than 5 drugs in different indications from lead identification to POC in man.
  • Glen Clack, MD, FFPM, CMO

    Glen has 20 years experience in oncology drug development and translational medicine. Before joining Octimet has held the position of senior medical director at AstraZeneca.; He holds various honorary academic positions and is a member of the oncology innovative medicines group. He was involved in the clinical development of anastrozole, cediranib, vandetanib, saracatinib.
  • Annegret Van der Aa, PhD, COO

    Annegret has a broad R&D experience in small and mid-size biotech (Innogenetics, ActoGeniX and Galapagos) for more than 15 years after obtaining a PhD in Biomedical Sciences. She took up increasing responsibilities from managing a research group, compound strategic and operational leadership to building a clinical development/operations department which resulted in the transitioning of more than 10 preclinical candidates to clinical stage products in a variety of indications.
  • Philip Owen, FCA, CFO

    Philip is an executive finance leader in both big and small companies with over 25 years experience. He is a qualified chartered accountant, tax adviser and corporate treasurer.
  • Marion Libouban, PhD, Translational Scientist

    Marion studied in France, Italy, UK, Germany and the Netherlands as well as having 2 years experience in biotech drug development where she managed external collaborations with academia and CRO’s. Marion has a strong background in the application of molecular biology, immunology and in vivo model development to Oncology.
  • Debbie Van Beylen, Office Manager, Project Planner

    Debbie has more than 12 years experience in office management and more than 5 years experience with clinical research.
  • Eric Ciamporcero, PhD, Translational Scientist

    Eric has 10 years experience in oncology, resulting in more than 20 publications. Trained in Italy as a molecular biologist, he then worked in a translational research lab in Buffalo (NY), USA, where he conducted, among others, in vivo studies to assess efficacy of MET inhibitors. Eric joined Octimet after two years at J&J where, as postodoctoral scientist, he led target identification efforts, mainly through collaboration with CROs.
  • Paolo Comoglio, MD, PhD, Scientific Advisor

    Paolo has more than 25 years experience with MET biology resulting in more than 300 publications. He is the Scientific Director of the Candiolo Cancer Institute – IRCCS in Turin, Italy. Prof Comoglio was one of the founding scientists of the MET biology field.
  • Ellen Jansen, Clinical Program Manager

    Ellen holds a Master in Biomedical Sciences and has more than 12 years experience in clinical operations, working for CRO (PPD), big pharma (J&J consultant) as well as for mid-sized biotech (Galapagos). The last 9 years she worked as a global clinical project lead and was responsible for managing clinical studies from Phase I up to Phase III in various indications.
  • Marc Tjwa, MD, PhD, Medical Director

    Marc has a broad R&D experience at various stages of (oncological) drug discovery and development. Trained as Medical Doctor at KU Leuven (Belgium), Marc has 13 years of experience in fundamental research on angiogenesis and oncology while obtaining a PhD in Medicine at KU Leuven, and subsequently heading a new research laboratory in Frankfurt (Germany). Marc achieved more than 60 research publications. He then switched from academia to government administration by joining, for the past 4 years, the Clinical Trials (CT) section of the FAMHP (Belgium) where Marc was pivotal in the medical assessment of CT applications, in part by conceptualizing new assessment tools.
  • 1

Investors

  • V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies (www.v-bio.ventures).
  • FUND+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium (www.fundplus.be).
  • DROIA is a venture capital investor focusing exclusively on oncology therapeutics (www.droia.be).
  • Omnes Capital is a major player in private equity and infrastructure with €3 billion in assets under management (www.omnescapital.com).
  • VIB is a life sciences research institute, based in Flanders, Belgium. We perform basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications (http://www.vib.be).
  • Flanders Innovation & Entrepreneurship supports all types of innovators in Flanders (http://www.vlaio.be).
  • 1

Partnering

OCTIMET is interested in discussing potential in- and out-licensing opportunities in translational oncology.

Please contact business development

Partnering
JLINX Incubator

Contact

OCTIMET Oncology NV

Turnhoutseweg 30, 2340 Beerse - Belgium

For general inquiries please contact

For business development inquiries please contact